Malgrat De Mar, Spain

Oriol Massot

This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2014.


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Oriol Massot

Introduction

Oriol Massot is a notable inventor based in Malgrat De Mar, Spain. He has made significant contributions to the field of chemistry, particularly in the development of innovative processes for chemical compounds. His work exemplifies the intersection of scientific research and practical application.

Latest Patents

Oriol Massot holds a patent for a process related to the preparation of a specific compound. The patent is titled "Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid." This invention pertains to a method for synthesizing a compound of formula (I), showcasing his expertise in chemical processes. He has 1 patent to his name.

Career Highlights

Oriol Massot is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role involves research and development, where he applies his innovative ideas to advance the company's objectives. His contributions have been instrumental in enhancing the company's portfolio of pharmaceutical products.

Collaborations

Throughout his career, Oriol has collaborated with esteemed colleagues, including Juan M Rodriguez Dehli and Xiao-Jun Wang. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation in their respective fields.

Conclusion

Oriol Massot's work as an inventor highlights the importance of innovation in the pharmaceutical industry. His patent and collaborations reflect a commitment to advancing scientific knowledge and improving healthcare solutions. His contributions will undoubtedly continue to influence the field for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…